Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons
This study is ongoing, but not recruiting participants.
Sponsor:
Uniformed Services University of the Health Sciences
Collaborator:
Infectious Diseases Clinical Research Program
Information provided by (Responsible Party):
Dr. Nancy Crum-Cianflone, Naval Health Research Center
ClinicalTrials.gov Identifier:
NCT00889577
First received: April 28, 2009
Last updated: January 18, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130305102451im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
The primary purpose of this study is to evaluate the association between nonalcoholic fatty liver disease (NAFLD) by computed tomography (CT) scan and coronary artery disease (CAD) measured by the calcium (CAC) score among HIV-infected persons.
Condition |
---|
HIV Infections Coronary Artery Disease Non-Alcoholic Fatty Liver Disease |
Study Type: | Observational |
Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
Official Title: | Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons |
Resource links provided by NLM:
Genetics Home Reference related topics:
complement factor I deficiency
MedlinePlus related topics:
CT Scans
Coronary Artery Disease
HIV/AIDS
High Blood Pressure
Liver Diseases
U.S. FDA Resources
Further study details as provided by Uniformed Services University of the Health Sciences:
Primary Outcome Measures:
- Coronary artery disease (CAD) measured by the CAC score [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To determine the prevalence of coronary artery disease as determined by computed tomography (CT) of the coronary arteries among HIV patients, and to compare it to data from the general population using normative data from recent publications [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- To evaluate predictors for coronary artery disease including demographics, concurrent conditions (e.g., diabetes, hyperlipidemia, tobacco use), and HIV factors such as ARV duration, HIV duration, and lipodystrophy [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- To investigate the relationship between inflammatory markers (CRP, ESR), d-dimer, adiponectin levels, future inflammatory markers, and genetic polymorphisms with the presence of coronary disease and NAFLD [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- To assess the relationship between increased pericardial fat on CT scan with visceral fat and cardiovascular disease [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- To determine if Hounsfield units taken in the heart and aorta estimates hemoglobin levels [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- To measure the pulmonary artery size to evaluate for prevalence of asymptomatic pulmonary hypertension among HIV-infected persons [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- To describe the outcome of a positive CAC score in terms of follow-up test/procedure results to help describe the clinical significance of elevated scores. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood samples will be obtained
Estimated Enrollment: | 300 |
Study Start Date: | December 2008 |
Estimated Study Completion Date: | January 2015 |
Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
![](https://webarchive.library.unt.edu/web/20130305102451im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Study Population
HIV positive patients who had participated in our previous Liver Study at NMCSD will be given the opportunity to participate in this study, as well as HIV patients who did not participate in the Liver Study.
Criteria
Inclusion Criteria:
- HIV patients who participated in our previous Liver Study, conducted at NMCSD, and HIV patients who did not participate in the Liver Study.
Exclusion Criteria:
- Women who are pregnant or breastfeeding will be excluded.
![](https://webarchive.library.unt.edu/web/20130305102451im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Please refer to this study by its ClinicalTrials.gov identifier: NCT00889577
Locations
United States, California | |
Naval Medical Center San Diego (NMCSD) | |
San Diego, California, United States, 92134 |
Sponsors and Collaborators
Uniformed Services University of the Health Sciences
Infectious Diseases Clinical Research Program
![](https://webarchive.library.unt.edu/web/20130305102451im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
Responsible Party: | Dr. Nancy Crum-Cianflone, Department Head, US Department of Defense Center for Deployment Health Research, Naval Health Research Center |
ClinicalTrials.gov Identifier: | NCT00889577 History of Changes |
Other Study ID Numbers: | IDCRP-018 |
Study First Received: | April 28, 2009 |
Last Updated: | January 18, 2013 |
Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Coronary Artery Disease Myocardial Ischemia Coronary Disease Fatty Liver Liver Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on March 03, 2013